Company Overview of Stempar Sciences, Inc.
Stempar Sciences, Inc. develops drugs for pancreatic, breast, and lung cancers. The company’s lead program is SPS-201, a therapeutic agent, which targets an enzyme frequently expressed at high levels by tumors. Its cancer drugs attacks solid tumors by simultaneously disrupting their source of energy and are able to repair chemotherapy/radiation induced DNA damage. The company also develops companion diagnostic tests to detect the NQO1 target protein. Stempar Sciences, Inc. was founded in 2009 and is based in Mill Valley, California.
35 Miller Avenue
Mill Valley, CA 94941
Founded in 2009
Key Executives for Stempar Sciences, Inc.
Similar Private Companies By Industry
|AbbVie Bioresearch Center Inc.||United States|
|Bracco U.S.A., Inc.||United States|
|Theracos, Inc.||United States|
|First Priority, Inc.||United States|
|Health Specialties Manufacturing, Inc.||United States|
Recent Private Companies Transactions
|No transactions available in the past 12 months.|
To contact Stempar Sciences, Inc., please visit stempar.com. Company data is provided by Capital IQ. Please use this form to report any data issues.